Efficacy and Safety of Bimagrumab/BYM338 at 52 Weeks on Physical Function, Muscle Strength, Mobility in sIBM Patients
Status:
Completed
Trial end date:
2016-01-06
Target enrollment:
Participant gender:
Summary
This study evaluated the efficacy, safety and tolerability of multiple doses of
bimagrumab/BYM338 vs placebo, when administered intravenously (i.v.), on physical function,
muscle strength, and mobility in patients with sporadic inclusion body myositis (sIBM).